IL6 and COVID-19: In this study, we identified that hospitalization due to COVID-19 was characterized by high levels of IL-6, MIG, IP-10, and IL-1R antagonist in the second week of illness and high levels of IL-6 in the first week of illness in comparison to milder illness in the community.